FLORENCE FALOLA: Open Payments
NPI 1306818679 · AUSTIN, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$857 in 30 payments from 10 companies in 2025. Trend: 2023 $1,286 · 2024 $1,003 · 2025 $857
Food & beverage: $842Education: $16
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 10 | $209 |
| GENZYME CORPORATION | 4 | $156 |
| Amgen Inc. | 1 | $140 |
| Novo Nordisk Inc | 2 | $116 |
| Janssen Biotech, Inc. | 5 | $95 |
| PFIZER INC. | 3 | $53 |
| Celltrion USA Inc. | 2 | $41 |
| Gilead Sciences, Inc. | 1 | $17 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $16 |
| Spinal Simplicity, LLC | 1 | $14 |
Products named: DUPIXENT, REPATHA, Wegovy, TREMFYA, LINZESS, CREON, VEGZELMA, XELJANZ.
Industry payments across TX — which companies pay providers there.
